Fig. 2From: Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohortsMultivariate analysis and meta-analysis summary demonstrate shorter melanoma-specific survival in middle aged (46–65) and older (>65) patients compared to patients age 45 or less at time of melanoma diagnosis, independent of melanoma stage or genderBack to article page